Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology

Bibliography

• Henshaw SK. Induced abortion: a world review, 1990. Fam Plann Perspect 1990;22:76-89
   PubMedGoogle Scholar
• Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid in vivo. VII International Congress of Pharmacology. Tokyo, Japan; 1981
   Google Scholar
• Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004;18:70-85
   PubMedGoogle Scholar
• Schreiber JR, Hsueh AJ, Baulieu EE. Binding of the anti-progestin RU-486 to rat ovary steroid receptors. Contraception 1983;28:77-85
   PubMed Web of Science ®Google Scholar
• el-Ashry D, Onate SA, Nordeen SK, Edwards DP. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 1989;3:1545-58
   PubMedGoogle Scholar
• DeMarzo AM, Onate SA, Nordeen SK, Edwards DP. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. Biochemistry 1992;31:10491-501
   PubMedGoogle Scholar
• Chalepakis G, Arnemann J, Slater E, Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus. Cell 1988;53:371-82
   PubMedGoogle Scholar
• Benhamou B, Garcia T, Lerouge T, A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 1992;255:206-9
   PubMed Web of Science ®Google Scholar
• Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-7
   PubMed Web of Science ®Google Scholar
• Wagner BL, Norris JD, Knotts TA, The nuclear corepressors NCoR and SMRT are key regulators of both ligand-and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998;18:1369-78
   PubMed Web of Science ®Google Scholar
• Vegeto E, Allan GF, Schrader WT, The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992;69:703-13
   PubMed Web of Science ®Google Scholar
• Kong EH, Pike AC, Hubbard RE. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 2003;31:56-9
   Google Scholar
• Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601-10
   PubMed Web of Science ®Google Scholar
• Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception 1989;39:103-17
   Web of Science ®Google Scholar
• Baird DT, Brown A, Critchley HO, Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-8
   PubMed Web of Science ®Google Scholar
• Loose DS, Stancel GM. Estrogens and progestins. In: Burton LL, Lazo JS, Parker KL, editors, Chapter 57. The phamacological basis of therapeutics. 11th edition. Goodman & Gilman's: McGraw-Hill, New York. Available from: http://www.accessmedicine.com/content.aspx?aID=953503
   Google Scholar
• Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-7
   PubMed Web of Science ®Google Scholar
• Chen BA, Creinin MD. Medical management of early pregnancy failure: efficacy. Semin Reprod Med 2008;26:411-22
   PubMed Web of Science ®Google Scholar
• Niinimaki M, Jouppila P, Martikainen H, Talvensaari-Mattila A. A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage. Fertil Steril 2006;86:367-72
   PubMed Web of Science ®Google Scholar
• Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception 2006;74:458-62
   Google Scholar
• Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev 2009;3:CD002865.
   Google Scholar
• Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task force on postovulatory methods of fertility regulation. Lancet 1999;353:697-702
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Piaggio G, Ding J, Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10
   PubMed Web of Science ®Google Scholar
• Glasier A, Thong KJ, Dewar M, Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-4
   PubMed Web of Science ®Google Scholar
• Glasier A, Thong KJ, Dewar M, Postcoital contraception with mifepristone. Lancet 1991;337:1414-15
   Google Scholar
• Hamoda H, Ashok PW, Stalder C, A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol 2004;104:1307-13
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Piaggio G. Levonorgestrel and mifepristone in emergency contraception. Steroids 2003;68:1107-13
   PubMed Web of Science ®Google Scholar
• Cheng L, Gülmezoglu AM, Piaggio G, Interventions for emergency contraception. Cochrane Database Syst Rev 2008;2:CD001324
   Google Scholar
• Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-3
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6
   PubMed Web of Science ®Google Scholar
• Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6
   PubMed Web of Science ®Google Scholar
• Fiscella K, Eisinger SH, Meldrum S, Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381-7
   PubMed Web of Science ®Google Scholar
• Engman M, Granberg S, Williams AR, Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009;24:1870-9
   PubMed Web of Science ®Google Scholar
• Escudero EL, Boerrigter PJ, Bennink HJ, Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2005;90:2081-8
   PubMed Web of Science ®Google Scholar
• Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev 2007;4:CD003449
   Google Scholar
• Benagiano G, Bastianelli C, Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother 2008;9:2487-96
   PubMed Web of Science ®Google Scholar
• Schoenlein PV, Hou M, Samaddar JS, Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 2007;31:643-55
   PubMedGoogle Scholar
• Klijn JG, de Jong FH, Bakker GH, Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49:2851-6
   PubMed Web of Science ®Google Scholar
• Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-30
   PubMed Web of Science ®Google Scholar
• Taplin ME, Manola J, Oh WK, A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 2008;101:1084-9
   Google Scholar
• Rocereto TF, Saul HM, Aikins JA Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-32
   PubMed Web of Science ®Google Scholar
• Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep 2009;22:1237-45
   Google Scholar
• Ramondetta LM, Johnson AJ, Sun CC, Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 2009;115:1867-74
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Russell CA, Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-33
   PubMed Web of Science ®Google Scholar
• Blasey CM, Debattista C, Roe R, A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials 2009;30:284-8
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Jurik J, Schatzberg LD, Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci 2002;19:201-6
   PubMedGoogle Scholar
• Phillips CI, Green K, Gore SM, Eye drops of RU 486-6, a peripheral steroid blocker, lower intraocular pressure in rabbits. Lancet 1984;1:767-8
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000;342:946-56
   PubMed Web of Science ®Google Scholar
• Fischer M, Bhatnagar J, Guarner J, Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005;353:2352-60
   PubMed Web of Science ®Google Scholar
• Fjerstad M, Trussell J, Sivin I, Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009;361:145-51
   PubMed Web of Science ®Google Scholar
• Virk J, Zhang J, Olsen J. Medical abortion and the risk of subsequent adverse pregnancy outcomes. N Engl J Med 2007;357:648-53
   PubMed Web of Science ®Google Scholar